Key facts
- It has raised $13.9M; the latest was Later Stage VC ($13.9M) in Jun 2025.
- Notable investors include Grower Venture Capital, Huyansuo Medical, Jinhe Capital, Sunz Fund, Yangpuwan Innovative Business Incubator.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for TreatGut
- ·The full record, as it builds
Funding rounds
No funding rounds for TreatGut are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About TreatGut
Developer of precision microbiota transplant therapy designed to deliver comprehensive solutions for human microecological health. The company's research focus is on the treatment and prevention of intestinal bacterial infections, enabling healthcare professionals to treat patients more effectively.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2016
- Employees
- 32
- Website
- treatgut.com/
- Ownership
- Privately Held (backing)
TreatGut doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in TreatGut shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on TreatGut in its N-PORT filings yet. We sweep new filings monthly.